Omidenepag Isopropyl (Omlonti) for Glaucoma

This is the authors' abstract. We don't add key points for this paper.

The FDA has approved Omlonti (Ocuvex), a 0.002% ophthalmic solution of the prostaglandin EP2 receptor agonist omidenepag isopropyl, for reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Omidenepag is the first selective prostaglandin EP2 receptor agonist to be approved in the US. It has been available in Japan since 2018.